Second generation CB1 receptor blockers and other inhibitors of peripheral endocannabinoid overactivity and the rationale of their use against metabolic disorders

Bibliography

• Expert Panel on the Identification E, and Treatment of Overweight in Adults. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: executive summary. expert panel on the identification, evaluation, and treatment of overweight in adults. Am J Clin Nutr 1998;68(4):899-917
   PubMed Web of Science ®Google Scholar
• WHO. Global strategy on diet, physical activity and health: obesity and overweight. 2012. Available from: http://www.who.int/dietphysicalactivity/publications/facts/obesity/en/
   Google Scholar
• Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999-2008. JAMA 2010;303(3):235-41
   PubMed Web of Science ®Google Scholar
• Malnick SD, Knobler H. The medical complications of obesity. QJM 2006;99(9):565-79
   PubMed Web of Science ®Google Scholar
• Mechoulam R. Discovery of endocannabinoids and some random thoughts on their possible roles in neuroprotection and aggression. Prostaglandins Leukot Essent Fatty Acids 2002;66(2-3):93-9
   PubMed Web of Science ®Google Scholar
• Pertwee RG. Cannabinoid pharmacology: the first 66 years. Br J Pharmacol 2006;147(Suppl 1):S163-71
   PubMed Web of Science ®Google Scholar
• Di Marzo V. Endocannabinoids: synthesis and degradation. Rev Physiol Biochem Pharmacol 2008;160:1-24
   PubMed Web of Science ®Google Scholar
• De Petrocellis L, Cascio MG, Di Marzo V. The endocannabinoid system: a general view and latest additions. Br J Pharmacol 2004;141(5):765-74
   PubMed Web of Science ®Google Scholar
• Di Marzo V, Petrosino S. Endocannabinoids and the regulation of their levels in health and disease. Curr Opin Lipidol 2007;18(2):129-40
   PubMed Web of Science ®Google Scholar
• Matias I, Bisogno T, Di Marzo V. Endogenous cannabinoids in the brain and peripheral tissues: regulation of their levels and control of food intake. Int J Obes (Lond) 2006;30(Suppl 1):S7-S12
   PubMedGoogle Scholar
• Kirkham TC. Cannabinoids and appetite: food craving and food pleasure. Int Rev Psychiatry 2009;21(2):163-71
   PubMed Web of Science ®Google Scholar
• Kirkham TC, Williams CM, Fezza F, Di Marzo V. Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol. Br J Pharmacol 2002;136(4):550-7
   PubMed Web of Science ®Google Scholar
• Di Marzo V, Goparaju SK, Wang L, Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 2001;410(6830):822-5
   PubMed Web of Science ®Google Scholar
• Wiley JL, Burston JJ, Leggett DC, CB1 cannabinoid receptor-mediated modulation of food intake in mice. Br J Pharmacol 2005;145(3):293-300
   PubMed Web of Science ®Google Scholar
• Poirier B, Bidouard JP, Cadrouvele C, The anti-obesity effect of rimonabant is associated with an improved serum lipid profile. Diabetes Obes Metab 2005;7(1):65-72
   PubMed Web of Science ®Google Scholar
• Ravinet Trillou C, Arnone M, Delgorge C, Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. Am J Physiol Regul Integr Comp Physiol 2003;284(2):R345-53
   PubMed Web of Science ®Google Scholar
• Cota D, Marsicano G, Tschop M, The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 2003;112(3):423-31
   PubMed Web of Science ®Google Scholar
• Ravinet Trillou C, Delgorge C, Menet C, CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity. Int J Obes Relat Metab Disord 2004;28(4):640-8
   PubMed Web of Science ®Google Scholar
• Di Marzo V, Matias I. Endocannabinoid control of food intake and energy balance. Nat Neurosci 2005;8(5):585-9
   PubMed Web of Science ®Google Scholar
• Bensaid M, Gary-Bobo M, Esclangon A, The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol 2003;63(4):908-14
   PubMed Web of Science ®Google Scholar
• Matias I, Gonthier MP, Orlando P, Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. J Clin Endocrinol Metab 2006;91(8):3171-80
   PubMed Web of Science ®Google Scholar
• Matias I, Petrosino S, Racioppi A, Dysregulation of peripheral endocannabinoid levels in hyperglycemia and obesity: effect of high fat diets. Mol Cell Endocrinol 2008;286(1-2 Suppl 1):S66-78
   PubMed Web of Science ®Google Scholar
• Pagotto U, Marsicano G, Cota D, The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev 2006;27(1):73-100
   PubMed Web of Science ®Google Scholar
• Osei-Hyiaman D, DePetrillo M, Pacher P, Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest 2005;115(5):1298-305
   PubMed Web of Science ®Google Scholar
• Jourdan T, Djaouti L, Demizieux L, CB1 antagonism exerts specific molecular effects on visceral and subcutaneous fat and reverses liver steatosis in diet-induced obese mice. Diabetes 2010;59(4):926-34
   PubMed Web of Science ®Google Scholar
• Quarta C, Bellocchio L, Mancini G, CB(1) signaling in forebrain and sympathetic neurons is a key determinant of endocannabinoid actions on energy balance. Cell Metab 2010;11(4):273-85
   PubMed Web of Science ®Google Scholar
• Monteleone P, Matias I, Martiadis V, Blood levels of the endocannabinoid anandamide are increased in anorexia nervosa and in binge-eating disorder, but not in bulimia nervosa. Neuropsychopharmacology 2005;30(6):1216-21
   PubMed Web of Science ®Google Scholar
• Engeli S, Bohnke J, Feldpausch M, Activation of the peripheral endocannabinoid system in human obesity. Diabetes 2005;54(10):2838-43
   PubMed Web of Science ®Google Scholar
• Cote M, Matias I, Lemieux I, Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese men. Int J Obes (Lond) 2007;31(4):692-9
   PubMed Web of Science ®Google Scholar
• Bluher M, Engeli S, Kloting N, Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity. Diabetes 2006;55(11):3053-60
   PubMed Web of Science ®Google Scholar
• Bordicchia M, Battistoni I, Mancinelli L, Cannabinoid CB1 receptor expression in relation to visceral adipose depots, endocannabinoid levels, microvascular damage, and the presence of the Cnr1 A3813G variant in humans. Metabolism 2010;59(5):734-41
   PubMed Web of Science ®Google Scholar
• Hajer GR, van Haeften TW, Visseren FL. Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. Eur Heart J 2008;29(24):2959-71
   PubMed Web of Science ®Google Scholar
• Despres JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature 2006;444(7121):881-7
   PubMed Web of Science ®Google Scholar
• Silvestri C, Ligresti A, Di Marzo V. Peripheral effects of the endocannabinoid system in energy homeostasis: adipose tissue, liver and skeletal muscle. Rev Endocr Metab Disord 2011;12(3):153-62
   PubMed Web of Science ®Google Scholar
• Mancini G, Quarta C, Srivastava RK, Adipocyte-specific CB1 conditional knock-out mice: new insights in the study of obesity and metabolic syndrome.
   Google Scholar
• Osei-Hyiaman D, Liu J, Zhou L, Hepatic CB1 receptor is required for development of diet-induced steatosis, dyslipidemia, and insulin and leptin resistance in mice. J Clin Invest 2008;118(9):3160-9
   PubMed Web of Science ®Google Scholar
• Pagano C, Pilon C, Calcagno A, The endogenous cannabinoid system stimulates glucose uptake in human fat cells via phosphatidylinositol 3-kinase and calcium-dependent mechanisms. J Clin Endocrinol Metab 2007;92(12):4810-19
   PubMed Web of Science ®Google Scholar
• Ruby MA, Nomura DK, Hudak CS, Overactive endocannabinoid signaling impairs apolipoprotein E-mediated clearance of triglyceride-rich lipoproteins. Proc Natl Acad Sci USA 2008;105(38):14561-6
   PubMed Web of Science ®Google Scholar
• Despres JP, Ross R, Boka G, Effect of rimonabant on the high-triglyceride/low-HDL-cholesterol dyslipidemia, intraabdominal adiposity, and liver fat: the ADAGIO-Lipids trial. Arterioscler Thromb Vasc Biol 2009;29(3):416-23
   PubMed Web of Science ®Google Scholar
• Di Marzo V, Cote M, Matias I, Changes in plasma endocannabinoid levels in viscerally obese men following a 1 year lifestyle modification programme and waist circumference reduction: associations with changes in metabolic risk factors. Diabetologia 2009;52(2):213-17
   PubMed Web of Science ®Google Scholar
• Jeong WI, Osei-Hyiaman D, Park O, Paracrine activation of hepatic CB1 receptors by stellate cell-derived endocannabinoids mediates alcoholic fatty liver. Cell Metab 2008;7(3):227-35
   PubMed Web of Science ®Google Scholar
• Jbilo O, Ravinet-Trillou C, Arnone M, The CB1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance. Faseb J 2005;19(11):1567-9
   PubMed Web of Science ®Google Scholar
• Tedesco L, Valerio A, Cervino C, Cannabinoid type 1 receptor blockade promotes mitochondrial biogenesis through endothelial nitric oxide synthase expression in white adipocytes. Diabetes 2008;57(8):2028-36
   PubMed Web of Science ®Google Scholar
• Flamment M, Gueguen N, Wetterwald C, Effects of the cannabinoid CB1 antagonist, rimonabant, on hepatic mitochondrial function in rats fed a high fat diet. Am J Physiol Endocrinol Metab 2009;297(5):E1162-70
   PubMed Web of Science ®Google Scholar
• Kola B, Hubina E, Tucci SA, Cannabinoids and ghrelin have both central and peripheral metabolic and cardiac effects via AMP-activated protein kinase. J Biol Chem 2005;280(26):25196-201
   PubMed Web of Science ®Google Scholar
• Cavuoto P, McAinch AJ, Hatzinikolas G, Effects of cannabinoid receptors on skeletal muscle oxidative pathways. Mol Cell Endocrinol 2007;267(1-2):63-9
   PubMed Web of Science ®Google Scholar
• Tedesco L, Valerio A, Dossena M, Cannabinoid receptor stimulation impairs mitochondrial biogenesis in mouse white adipose tissue, muscle, and liver: the role of eNOS, p38 MAPK, and AMPK pathways. Diabetes 2010;59(11):2826-36
   PubMed Web of Science ®Google Scholar
• Abdul-Ghani MA, DeFronzo RA. Pathogenesis of insulin resistance in skeletal muscle. J Biomed Biotechnol 2010;2010:476279
   PubMedGoogle Scholar
• Nogueiras R, Veyrat-Durebex C, Suchanek PM, Peripheral, but not central, CB1 antagonism provides food intake-independent metabolic benefits in diet-induced obese rats. Diabetes 2008;57(11):2977-91
   PubMed Web of Science ®Google Scholar
• Perwitz N, Fasshauer M, Klein J. Cannabinoid receptor signaling directly inhibits thermogenesis and alters expression of adiponectin and visfatin. Horm Metab Res 2006;38(5):356-8
   PubMed Web of Science ®Google Scholar
• Gary-Bobo M, Elachouri G, Scatton B, The cannabinoid CB1 receptor antagonist rimonabant (SR141716) inhibits cell proliferation and increases markers of adipocyte maturation in cultured mouse 3T3 F442A preadipocytes. Mol Pharmacol 2006;69(2):471-8
   PubMed Web of Science ®Google Scholar
• Despres JP, Golay A, Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005;353(20):2121-34
   PubMed Web of Science ®Google Scholar
• Lindborg KA, Teachey MK, Jacob S, Henriksen EJ. Effects of in vitro antagonism of endocannabinoid-1 receptors on the glucose transport system in normal and insulin-resistant rat skeletal muscle. Diabetes Obes Metab 2010;12(8):722-30
   PubMed Web of Science ®Google Scholar
• Esposito I, Proto MC, Gazzerro P, The cannabinoid CB1 receptor antagonist rimonabant stimulates 2-deoxyglucose uptake in skeletal muscle cells by regulating the expression of phosphatidylinositol-3-kinase. Mol Pharmacol 2008;74(6):1678-86
   PubMed Web of Science ®Google Scholar
• Lipina C, Stretton C, Hastings S, Regulation of MAP kinase-directed mitogenic and protein kinase B-mediated signaling by cannabinoid receptor type 1 in skeletal muscle cells. Diabetes 2010;59(2):375-85
   PubMed Web of Science ®Google Scholar
• Greasley PJ, Clapham JC. Inverse agonism or neutral antagonism at G-protein coupled receptors: a medicinal chemistry challenge worth pursuing? Eur J Pharmacol 2006;553(1-3):1-9
   PubMed Web of Science ®Google Scholar
• Pertwee RG. Inverse agonism and neutral antagonism at cannabinoid CB1 receptors. Life Sci 2005;76(12):1307-24
   PubMed Web of Science ®Google Scholar
• Giraldo J. How inverse can a neutral antagonist be? Strategic questions after the rimonabant issue. Drug Discov Today 2010;15(11-12):411-15
   PubMed Web of Science ®Google Scholar
• Sink KS, Vemuri VK, Wood J, Oral bioavailability of the novel cannabinoid CB1 antagonist AM6527: effects on food-reinforced behavior and comparisons with AM4113. Pharmacol Biochem Behav 2009;91(3):303-6
   PubMed Web of Science ®Google Scholar
• Chambers AP, Vemuri VK, Peng Y, A neutral CB1 receptor antagonist reduces weight gain in rat. Am J Physiol Regul Integr Comp Physiol 2007;293(6):R2185-93
   PubMed Web of Science ®Google Scholar
• Sink KS, McLaughlin PJ, Wood JA, The novel cannabinoid CB1 receptor neutral antagonist AM4113 suppresses food intake and food-reinforced behavior but does not induce signs of nausea in rats. Neuropsychopharmacology 2008;33(4):946-55
   PubMed Web of Science ®Google Scholar
• Sink KS, Segovia KN, Collins LE, The CB1 inverse agonist AM251, but not the CB1 antagonist AM4113, enhances retention of contextual fear conditioning in rats. Pharmacol Biochem Behav 2010;95(4):479-84
   PubMed Web of Science ®Google Scholar
• Sink KS, Segovia KN, Sink J, Potential anxiogenic effects of cannabinoid CB1 receptor antagonists/inverse agonists in rats: comparisons between AM4113, AM251, and the benzodiazepine inverse agonist FG-7142. Eur Neuropsychopharmacol 2010;20(2):112-22
   PubMed Web of Science ®Google Scholar
• Cluny NL, Chambers AP, Vemuri VK, The neutral cannabinoid CB receptor antagonist AM4113 regulates body weight through changes in energy intake in the rat. Pharmacol Biochem Behav 2011;97(3):537-43
   PubMed Web of Science ®Google Scholar
• Limebeer CL, Vemuri VK, Bedard H, Inverse agonism of cannabinoid CB1 receptors potentiates LiCl-induced nausea in the conditioned gaping model in rats. Br J Pharmacol 2010;161(2):336-49
   PubMed Web of Science ®Google Scholar
• Bostrom J, Olsson RI, Tholander J, Novel thioamide derivatives as neutral CB1 receptor antagonists. Bioorg Med Chem Lett 2010;20(2):479-82
   PubMed Web of Science ®Google Scholar
• Hurst DP, Lynch DL, Barnett-Norris J, N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole -3-carboxamide (SR141716A) interaction with LYS 3.28(192) is crucial for its inverse agonism at the cannabinoid CB1 receptor. Mol Pharmacol 2002;62(6):1274-87
   PubMed Web of Science ®Google Scholar
• Fride E, Braun H, Matan H, Inhibition of milk ingestion and growth after administration of a neutral cannabinoid CB1 receptor antagonist on the first postnatal day in the mouse. Pediatr Res 2007;62(5):533-6
   PubMed Web of Science ®Google Scholar
• Mechoulam R, Berry EM, Avraham Y, Endocannabinoids, feeding and suckling–from our perspective. Int J Obes (Lond) 2006;30(Suppl 1):S24-8
   PubMedGoogle Scholar
• Tseng SL, Hung MS, Chang CP, Bioisosteric replacement of the pyrazole 5-aryl moiety of N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole -3-carboxamide (SR141716A). A novel series of alkynylthiophenes as potent and selective cannabinoid-1 receptor antagonists. J Med Chem 2008;51(17):5397-412
   PubMed Web of Science ®Google Scholar
• Lin Y, Shia KS, Hsiao WC, Biphasic suppression of appetite by cannabinoid CB1 receptor antagonists with distinct functional activities. Pharmacol Res 2010;62(4):337-43
   PubMed Web of Science ®Google Scholar
• Shim JY, Welsh WJ, Cartier E, Molecular interaction of the antagonist N-(piperidin-1-yl)-5-(4-chlorophenyl)-1- (2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide with the CB1 cannabinoid receptor. J Med Chem 2002;45(7):1447-59
   PubMed Web of Science ®Google Scholar
• Higuchi S, Irie K, Mishima S, The cannabinoid 1-receptor silent antagonist O-2050 attenuates preference for high-fat diet and activated astrocytes in mice. J Pharmacol Sci 2010;112(3):369-72
   PubMed Web of Science ®Google Scholar
• Sano K, Koushi E, Irie K, Delta(9)-tetrahydrocannabinol enhances an increase of plasma corticosterone levels induced by forced swim-stress. Biol Pharm Bull 2009;32(12):2065-7
   PubMed Web of Science ®Google Scholar
• Wiley JL, Breivogel CS, Mahadevan A, Structural and pharmacological analysis of O-2050, a putative neutral cannabinoid CB(1) receptor antagonist. Eur J Pharmacol 2011;651(1-3):96-105
   PubMed Web of Science ®Google Scholar
• Bertalovitz AC, Ahn KH, Kendall DA. Ligand Binding Sensitivity of the Extracellular Loop Two of the Cannabinoid Receptor 1. Drug Dev Res 2010;71(7):404-11
   PubMed Web of Science ®Google Scholar
• Gardner A, Mallet PE. Suppression of feeding, drinking, and locomotion by a putative cannabinoid receptor 'silent antagonist'. Eur J Pharmacol 2006;530(1-2):103-6
   PubMed Web of Science ®Google Scholar
• Makwana R, Molleman A, Parsons ME. Evidence for both inverse agonism at the cannabinoid CB1 receptor and the lack of an endogenous cannabinoid tone in the rat and guinea-pig isolated ileum myenteric plexus-longitudinal muscle preparation. Br J Pharmacol 2010;160(3):615-26
   PubMed Web of Science ®Google Scholar
• 7TM Pharma press release. Available from: http://www.7tm.dk/News.aspx
   Google Scholar
• Fridberg M, Little PB, Cooper M, A single ascending dose study of TM38837 – a novel second generation peripheral selective CB1 receptor antagonist in healthy male subjects. 2010
   Google Scholar
• Receveur JM, Murray A, Linget JM, Conversion of 4-cyanomethyl-pyrazole-3-carboxamides into CB1 antagonists with lowered propensity to pass the blood-brain-barrier. Bioorg Med Chem Lett 2010;20(2):453-7
   PubMed Web of Science ®Google Scholar
• Jagerovic N, Hernandez-Folgado L, Alkorta I, Discovery of 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-hexyl-1h-1,2,4-triazole, a novel in vivo cannabinoid antagonist containing a 1,2,4-triazole motif. J Med Chem 2004;47(11):2939-42
   PubMed Web of Science ®Google Scholar
• Pavon FJ, Serrano A, Perez-Valero V, Central versus peripheral antagonism of cannabinoid CB1 receptor in obesity: effects of LH-21, a peripherally acting neutral cannabinoid receptor antagonist, in Zucker rats. J Neuroendocrinol 2008;20(Suppl 1):116-23
   PubMed Web of Science ®Google Scholar
• Pavon FJ, Bilbao A, Hernandez-Folgado L, Antiobesity effects of the novel in vivo neutral cannabinoid receptor antagonist 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-3-hexyl-1H-1,2,4-triazole–LH 21. Neuropharmacology 2006;51(2):358-66
   PubMed Web of Science ®Google Scholar
• Alonso M, Serrano A, Anti-obesity efficacy of LH-21, a cannabinoid CB(1) receptor antagonist with poor brain penetration, in diet-induced obese rats. Br J Pharmacol 2012;165(7):2274-2291
   PubMed Web of Science ®Google Scholar
• Chen RZ, Frassetto A, Lao JZ, Pharmacological evaluation of LH-21, a newly discovered molecule that binds to cannabinoid CB1 receptor. Eur J Pharmacol 2008;584(2-3):338-42
   PubMed Web of Science ®Google Scholar
• LoVerme J, Duranti A, Tontini A, Synthesis and characterization of a peripherally restricted CB1 cannabinoid antagonist, URB447, that reduces feeding and body-weight gain in mice. Bioorg Med Chem Lett 2009;19(3):639-43
   PubMed Web of Science ®Google Scholar
• DiPatrizio NV, Astarita G, Schwartz G, Endocannabinoid signal in the gut controls dietary fat intake. Proc Natl Acad Sci USA 2011;108(31):12904-8
   PubMed Web of Science ®Google Scholar
• Son MH, Kim HD, Chae YN, Peripherally acting CB1-receptor antagonist: the relative importance of central and peripheral CB1 receptors in adiposity control. Int J Obes (Lond) 2010;34(3):547-56
   PubMed Web of Science ®Google Scholar
• Tam J, Vemuri VK, Liu J, Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity. J Clin Invest 2010;120(8):2953-66
   PubMed Web of Science ®Google Scholar
• Cluny NL, Vemuri VK, Chambers AP, A novel peripherally restricted cannabinoid receptor antagonist, AM6545, reduces food intake and body weight, but does not cause malaise, in rodents. Br J Pharmacol 2010;161(3):629-42
   PubMed Web of Science ®Google Scholar
• Jarbe TU, LeMay BJ, Vemuri VK, Central mediation and differential blockade by cannabinergics of the discriminative stimulus effects of the cannabinoid CB1 receptor antagonist rimonabant in rats. Psychopharmacology (Berl) 2011;216(3):355-65
   PubMed Web of Science ®Google Scholar
• Randall PA, Vemuri VK, Segovia KN, The novel cannabinoid CB1 antagonist AM6545 suppresses food intake and food-reinforced behavior. Pharmacol Biochem Behav 2010;97(1):179-84
   PubMed Web of Science ®Google Scholar
• Kunos G. Peripheral CB1 receptor inverse agonism is equieffective with global CB1 blockade in reversing diet-induced obesity and its metabolic complications. 5th Diabetes Drug Discovery & Development; Boston, MA, USA: 2012
   Google Scholar
• Hortala L, Rinaldi-Carmona M, Congy C, Rational design of a novel peripherally-restricted, orally active CB(1) cannabinoid antagonist containing a 2,3-diarylpyrrole motif. Bioorg Med Chem Lett 2010;20(15):4573-7
   PubMed Web of Science ®Google Scholar
• Hung MS, Chang CP, Li TC, Discovery of 1-(2,4-dichlorophenyl)-4-ethyl-5-(5-(2-(4-(trifluoromethyl)phenyl)ethynyl)thiophe n-2-yl)-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide as a potential peripheral cannabinoid-1 receptor inverse agonist. ChemMedChem 2010;5(9):1439-43
   PubMed Web of Science ®Google Scholar
• Fulp A, Bortoff K, Zhang Y, Towards rational design of cannabinoid receptor 1 (CB1) antagonists for peripheral selectivity. Bioorg Med Chem Lett 2011;21(19):5711-14
   PubMed Web of Science ®Google Scholar
• Fulp A, Bortoff K, Seltzman H, Design and synthesis of cannabinoid receptor 1 antagonists for peripheral selectivity. J Med Chem 2012;55(6):2820-34
   PubMed Web of Science ®Google Scholar
• Cottrell GT, Ferguson AV. Sensory circumventricular organs: central roles in integrated autonomic regulation. Regul Pept 2004;117(1):11-23
   PubMed Web of Science ®Google Scholar
• Van Sickle MD, Oland LD, Mackie K, Delta9-tetrahydrocannabinol selectively acts on CB1 receptors in specific regions of dorsal vagal complex to inhibit emesis in ferrets. Am J Physiol Gastrointest Liver Physiol 2003;285(3):G566-76
   PubMed Web of Science ®Google Scholar
• Partosoedarso ER, Abrahams TP, Scullion RT, Cannabinoid1 receptor in the dorsal vagal complex modulates lower oesophageal sphincter relaxation in ferrets. J Physiol 2003;550(Pt 1):149-58
   PubMed Web of Science ®Google Scholar
• Ahima RS, Saper CB, Flier JS, Elmquist JK. Leptin regulation of neuroendocrine systems. Front Neuroendocrinol 2000;21(3):263-307
   PubMed Web of Science ®Google Scholar
• Agudo J, Martin M, Roca C, Deficiency of CB2 cannabinoid receptor in mice improves insulin sensitivity but increases food intake and obesity with age. Diabetologia 2010;53(12):2629-40
   PubMed Web of Science ®Google Scholar
• Deveaux V, Cadoudal T, Ichigotani Y, Cannabinoid CB2 receptor potentiates obesity-associated inflammation, insulin resistance and hepatic steatosis. PLoS One 2009;4(6):e5844
   PubMedGoogle Scholar
• Bisogno T, Burston JJ, Rai R, Synthesis and pharmacological activity of a potent inhibitor of the biosynthesis of the endocannabinoid 2-arachidonoylglycerol. ChemMedChem 2009;4(6):946-50
   PubMed Web of Science ®Google Scholar
• Jung KM, Clapper JR, Fu J, 2-arachidonoylglycerol signaling in forebrain regulates systemic energy metabolism. Cell Metab 2012;15(3):299-310
   PubMed Web of Science ®Google Scholar
• Bisogno T, Cascio MG, Saha B, Development of the first potent and specific inhibitors of endocannabinoid biosynthesis. Biochim Biophys Acta 2006;1761(2):205-12
   PubMed Web of Science ®Google Scholar
• Schuchardt JP, Schneider I, Meyer H, Incorporation of EPA and DHA into plasma phospholipids in response to different omega-3 fatty acid formulations–a comparative bioavailability study of fish oil vs. krill oil. Lipids Health Dis 2011;10:145
   PubMed Web of Science ®Google Scholar
• Kinsella JE.. Lipids, membrane receptors, and enzymes: effects of dietary fatty acids. JPEN J Parenter Enteral Nutr 1990;14(5 Suppl):200S-17S
   PubMed Web of Science ®Google Scholar
• Matias I, Carta G, Murru E, Effect of polyunsaturated fatty acids on endocannabinoid and N-acyl-ethanolamine levels in mouse adipocytes. Biochim Biophys Acta 2008;1781(1-2):52-60
   PubMed Web of Science ®Google Scholar
• Alvheim AR, Malde MK, Osei-Hyiaman D, Dietary Linoleic Acid Elevates Endogenous 2-AG and Anandamide and Induces Obesity. Obesity (Silver Spring) 2012; doi:10.1038/oby.2012.38.
   Google Scholar
• Di Marzo V, Griinari M, Carta G, Dietary krill oil increases docosahexaenoic acid and reduces 2-arachidonoylglycerol but not N-acylethanolamine levels in the brain of obese Zucker rats. Int Dairy J 2010;20(4):231-5
   Web of Science ®Google Scholar
• Banni S, Carta G, Murru E, Krill oil significantly decreases 2-arachidonoylglycerol plasma levels in obese subjects. Nutr Metab (Lond) 2011;8(1):7
   PubMedGoogle Scholar
• Piscitelli F, Carta G, Bisogno T, Effect of dietary krill oil supplementation on the endocannabinoidome of metabolically relevant tissues from high-fat-fed mice. Nutr Metab (Lond) 2011;8(1):51
   PubMedGoogle Scholar
• Batetta B, Griinari M, Carta G, Endocannabinoids may mediate the ability of (n-3) fatty acids to reduce ectopic fat and inflammatory mediators in obese Zucker rats. J Nutr 2009;139(8):1495-501
   PubMed Web of Science ®Google Scholar
• Liu J, Zhou L, Xiong K, Hepatic cannabinoid receptor-1 mediates diet-induced insulin resistance via inhibition of insulin signaling and clearance in mice. Gastroenterology 2012;142(5):1218-1228 e1211
   PubMed Web of Science ®Google Scholar
• Schuchardt JP, Neubronner J, Kressel G, Moderate doses of EPA and DHA from re-esterified triacylglycerols but not from ethyl-esters lower fasting serum triacylglycerols in statin-treated dyslipidemic subjects: results from a six month randomized controlled trial. Prostaglandins Leukot Essent Fatty Acids 2011;85(6):381-6
   PubMed Web of Science ®Google Scholar
• Buettner C, Muse ED, Cheng A, Leptin controls adipose tissue lipogenesis via central, STAT3-independent mechanisms. Nat Med 2008;14(6):667-75
   PubMed Web of Science ®Google Scholar
• O'Hare JD, Zielinski E, Cheng B, Central endocannabinoid signaling regulates hepatic glucose production and systemic lipolysis. Diabetes 2011;60(4):1055-62
   PubMed Web of Science ®Google Scholar